Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 20/20 | 0.80 |
| ▸ | AKR1B1 | P15121 | 9/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1249493 | 0.89 | PTGDR2 (1.00) | PTGDR2AKR1B1CYP2C9SLC6A4 | |
| SCHEMBL11891659 | 0.88 | PTGDR2 (0.66) | PTGDR2AKR1B1CYP2C9SLC6A4 | |
| SCHEMBL13952927 | 0.85 | PTGDR2 (0.83) | PTGDR2AKR1B1CYP2C9SLC6A4 | |
| SCHEMBL1406045 | 0.85 | PTGDR2 (1.00) | PTGDR2AKR1B1CYP2C9SLC6A4 | |
| SCHEMBL27970154 | 0.84 | PTGDR2 (0.58) | PTGDR2AKR1B1CYP2C9SLC6A4 | |
| SCHEMBL1249481 | 0.83 | PTGDR2 (0.79) | PTGDR2AKR1B1CYP2C9SLC6A4 | |
| SCHEMBL1405972 | 0.83 | PTGDR2 (0.79) | PTGDR2AKR1B1CYP2C9SLC6A4 | |
| SCHEMBL1406277 | 0.83 | PTGDR2 (0.79) | PTGDR2AKR1B1CYP2C9SLC6A4 | |
| Azd1981 SCHEMBL1053662 | 0.81 | PTGDR2 (1.00) | PTGDR2AKR1B1CYP2C9SLC6A4 | |
| Azd1981 SCHEMBL30538014 | 0.81 | PTGDR2 (1.00) | PTGDR2AKR1B1CYP2C9SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2451780-B1 | INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF 4-(ACETYLAMINO))-3-[(4-CHLORO-PHENYL)THIO]-2-METHYL-1H-INDOLE-1-ACETIC ACID | ASTRAZENECA AB (SE) | 2013-06-19 | — | — | EP | disclosed |
| US-8227622-B2 | Pharmaceutical process and intermediates 714 | ASTRAZENECA AB (SE) | 2012-07-24 | — | — | US | disclosed |
| US-8227622-B2 | Pharmaceutical process and intermediates 714 | ASTRAZENECA AB (SE) | 2012-07-24 | — | — | US | disclosed |
| EP-2451780-A1 | INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF 4- (ACETYLAMINO) ) -3- [ (4-CHLORO-PHENYL) THIO]-2-METHYL-1H-INDOLE-1-ACETIC ACID | AstraZeneca AB (SE) | 2012-05-16 | — | — | EP | disclosed |
| US-20110046394-A1 | Pharmaceutical Process and Intermediates 714 | ASTRAZENECA AB (SE) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046394-A1 | Pharmaceutical Process and Intermediates 714 | CYP3A4, CYP4A11, CYP4B1 | PTGDR2 3430/4885AKR1B1 298/4885CYP2C9 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.